Trial Profile
Safety of Flibanserin Versus Placebo in Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Flibanserin (Primary)
- Indications Anxiety disorders; Depressive disorders; Premenstrual dysphoric disorder
- Focus Adverse reactions; Registrational
- Sponsors Boehringer Ingelheim Pharmaceuticals; Sprout Pharmaceuticals
- 22 May 2013 Results presented at the 166th Annual Meeting of the American Psychiatric Association.
- 02 Mar 2012 Sprout Pharmaceuticals as company and lead trial centre added as reported by ClinicalTrials.gov.
- 18 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.